Arbutus Biopharma Highlights Imdusiran at AASLD 2024
Arbutus Biopharma Corporation (NASDAQ: ABUS) is making waves in the biopharmaceutical industry with its innovative research around imdusiran, an RNA interference (RNAi) therapeutic designed to combat chronic hepatitis B virus (cHBV) infection. During the upcoming American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting 2024, scheduled for November 15-19, in San Diego, California, the company will present four insightful posters featuring its latest clinical data.
Clinical Data and Poster Presentations
At the AASLD 2024, two late-breaking posters will focus on key findings from the IM-PROVE I and IM-PROVE II Phase 2a clinical trials, which are crucial in understanding the effectiveness of imdusiran. One of the noteworthy presentations titled, "Soluble Immune Biomarker Profiling of Chronic Hepatitis B Subjects Treated with Imdusiran in Combination with Pegylated Interferon (IFN) Alfa Reveals Phases of Immune Activation," will be presented by Emily Thi, Arbutus' Senior Director of Immunobiology and Biomarkers Research.
Key Findings from the Poster Presentations
The findings demonstrate that imdusiran treatment in concert with interferon results in identifiable phases of immune biomarker signatures. In the initial treatment period, there were notable immune responses associated with Th1 activation, coinciding with significant reductions in hepatitis B surface antigen (HBsAg). This showcases the potential for imdusiran to not only target the virus effectively but also help restore the immune system's capacity to respond to it.
The second poster presentation will delve into the conservation of the HBV target site for imdusiran across different patient samples. This analysis is pivotal because it indicates that the viral target remains consistent even among different HBV variants, enhancing confidence in the therapeutic's broad applicability against multiple genotypes A-E.
Availability of Poster Presentations
Interested parties can access these groundbreaking presentations on the Arbutus website beginning November 15, 2024. The company plans to make its poster presentations available in the Publications section of its website. They're excited to share this data with healthcare professionals and stakeholders in the industry, reinforcing its commitment to developing effective treatments for HBV.
Understanding Imdusiran and Its Potential Impact
Imdusiran operates through a unique mechanism aimed at reducing all HBV viral proteins and antigens, particularly the hepatitis B surface antigen. By effectively targeting hepatocytes through innovative delivery systems, imdusiran represents a leap forward in the ongoing fight against chronic HBV infection.
So far, clinical data indicates that imdusiran is well-tolerated, presenting compelling evidence of its efficacy. This therapeutic aims not only to diminish the viral load but also to stimulate the immune response against HBV, which is crucial for achieving long-term patient outcomes. As Arbutus continues its Phase 2a trials, anticipation grows around its potential to shift how hepatitis B is treated.
The Challenge of Hepatitis B
Hepatitis B remains a global health challenge, afflicting millions and leading to severe complications, including liver cirrhosis and cancer. The World Health Organization estimates that around 250 million people globally live with chronic HBV, highlighting the need for robust treatment solutions. Traditional treatment methods have limitations, often falling short of eradicating the virus. Thus, the introduction of novel therapies like imdusiran could be transformative.
Crucially, despite available vaccines and treatments, many still face devastating outcomes each year due to HBV-related complications. The urgency to find solutions that not only manage but also cure hepatitis B cannot be overstated.
About Arbutus Biopharma
Arbutus Biopharma is at the forefront of developing novel therapeutic approaches that hold the promise of a functional cure for chronic hepatitis B. The company combines virology expertise with advanced drug development to create treatments that address the root causes of HBV infection. Besides imdusiran, its pipeline includes an oral PD-L1 inhibitor, AB-101, currently undergoing evaluation in clinical settings.
Frequently Asked Questions
What is imdusiran?
Imdusiran is an RNA interference therapeutic developed by Arbutus Biopharma aimed at reducing HBV viral proteins and antigens.
When will Arbutus Biopharma present its data?
The data will be presented during the AASLD - The Liver Meeting 2024, scheduled for November 15-19.
What are the potential benefits of imdusiran?
Imdusiran may potentially reduce hepatitis B surface antigen and amplify immune responses against HBV, offering hope for a cure.
How many poster presentations will Arbutus have?
Arbutus will present four poster presentations highlighting its clinical findings related to imdusiran.
Is there ongoing research for chronic HBV treatments?
Yes, Arbutus Biopharma is actively engaged in developing new treatments, including Phase 2a trials for imdusiran and other compounds.
